Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Hypertension ; 19(4): 345-54, 1992 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-1555866

RESUMO

This article reports on the binding and the angiotensin II (Ang II) antagonistic properties of a peptide, referred to as hIIA, encoded by an RNA strand complementary to the human Ang II messenger RNA. Although Ang II and hIIA (H2N-Glu-Gly-Val-Tyr-Val-His-Pro-Val-COOH) share four amino acids, the iodinated and tritiated forms of hIIA were unreactive with seven monoclonal antibodies defining four distinct epitopes on the Ang II molecule and failed to bind to Ang II hepatic and mesangial receptors. However, hIIA did inhibit binding of 125I-Ang II to rat hepatocyte membranes (IC50, 2 x 10(-7) M) and to the various monoclonal antibodies. The lowest IC50 (5 x 10(-7) M) was measured with the monoclonal antibody specific for the Ang II sequence generally considered as implicated in receptor recognition. As predicted from the binding studies, hIIA was further shown to antagonize some biological properties of Ang II. On mesangial cells, hIIA alone had no effect on intracellular calcium concentration ([Ca2+]i) and prostaglandin E2 synthesis but did abolish the transient increase in [Ca2+]i in response to 100 nM Ang II and did induce a specific dose-dependent inhibition of the Ang II-stimulated prostaglandin E2 release. Furthermore, intravenous infusion of hIIA (200 micrograms.kg-1.min-1) inhibited by 66 +/- 3% the rat hypertensive response to 100 ng.kg-1 Ang II but had no effect on the pressor activity of agents such as alpha 1-adrenergic and HT2 serotonin agonists. Our data suggest that the "complementary" peptide hIIA interacts directly with Ang II by mimicking the Ang II complementary site on the receptor and can inhibit the physiological effects of Ang II. This type of Ang II complementary peptide may serve as a model for a new class of antihypertensive drugs.


Assuntos
Angiotensina II/antagonistas & inibidores , Angiotensina II/química , Oligopeptídeos/farmacologia , RNA Mensageiro/química , Sequência de Aminoácidos , Angiotensina II/genética , Antagonistas de Receptores de Angiotensina , Animais , Anticorpos Monoclonais/metabolismo , Sequência de Bases , Cálcio/metabolismo , Dinoprostona/biossíntese , Relação Dose-Resposta a Droga , Hipertensão/induzido quimicamente , Hipertensão/prevenção & controle , Masculino , Dados de Sequência Molecular , Oligopeptídeos/química , Oligopeptídeos/metabolismo , Ratos , Ratos Endogâmicos , Receptores de Angiotensina/metabolismo
3.
Int J Pept Protein Res ; 17(4): 480-5, 1981 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-7309351

RESUMO

Energy optimizations were performed on some typical conformations of the gastrin C-terminal peptide amide NAc-Trp-Met-Asp-Phe-NH2. Two families of lowest energy conformations were found corresponding to: (a) alpha-helical structures; (b) conformations having beta-structure at the level of Trp residue, and C7-structure at the level of Asp residue. The two aromatic rings were folded on the peptide backbone and ca. 5 A distant from each other (centre to centre). The last family, favoured by energy and population probability, can better account for conformational experimental results and biological activity observations.


Assuntos
Gastrinas , Sequência de Aminoácidos , Modelos Moleculares , Oligopeptídeos , Conformação Proteica , Relação Estrutura-Atividade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA